SEER
Seer, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.38
P/S
5.82
EV/EBITDA
-1.13
DCF Value
$-12.02
FCF Yield
-47.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
51.1%
Operating Margin
-470.5%
Net Margin
-444.0%
ROE
-26.0%
ROA
-24.9%
ROIC
-27.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $4.2M | $-16.0M | $-0.29 |
| FY 2025 | $16.6M | $-73.6M | $-1.28 |
| Q3 2025 | $4.1M | $-18.2M | $-0.32 |
| Q2 2025 | $4.1M | $-19.4M | $-0.33 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.60
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.